Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04340050
Other study ID # IRB20-0523
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date April 10, 2020
Est. completion date December 23, 2020

Study information

Verified date February 2024
Source University of Chicago
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the feasibility of delivering anti-SARS-CoV-2 convalescent plasma to hospitalized patients with severe or life-threatening COVID-19. Beyond supportive care, there are currently no proven treatment options for coronavirus disease (COVID-19), the infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Human convalescent plasma is an option for treatment of COVID-19 and could be rapidly available when there are sufficient numbers of people who have recovered and can donate high titer neutralizing immunoglobulin-containing plasma. Hypothesis: Collecting and administering convalescent plasma requires a level of logistical coordination that is not available in all centers. Objective: To establish feasibility for a hospital-based integrated system to collect and administer convalescent plasma to patients with severe or life-threatening COVID-19.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date December 23, 2020
Est. primary completion date December 23, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Donor Inclusion Criteria: - Age greater or equal to 18 - Able to donate blood per blood bank standard guidelines - Prior diagnosis of COVID-19 documented by a laboratory test (confirmed) - Complete resolution of symptoms at least 28 days prior to donation - Female donors who have never been pregnant, previously pregnant female donors negative for HLA antibodies (HLA screening), or male donors Donor Exclusion Criteria: - Does not provide consent - Does not meet standard blood bank donation guidelines - Unsuccessful blood donation Recipient Inclusion Criteria: - Patients must be 18 years of age or older - Must have laboratory-confirmed COVID-19 - Must have severe or immediately life-threatening COVID-19 - Severe defined as dyspnea, respiratory frequency = 30/min, blood oxygen saturation = 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, and/or lung infiltrates > 50% within 24 to 48 hours - Life-threatening defined as respiratory failure, septic shock, and/or multiple organ dysfunction or failure. Lower priority should be given to patients with septic shock or multiple organ dysfunction or failure since their disease may have progressed to a point where they are not able to benefit from convalescent plasma therapy. - Must be less than 21 days from the start of illness - Patient is willing and able to provide written informed consent and comply with all protocol requirements. If the patient is not able to consent, we will obtain consent from the power of attorney or a health care proxy for the patient as determined by the Illinois Healthcare Surrogate Act - Patient, power of attorney or health care proxy agrees to storage of specimens for future testing. - Of note, eIND application for each recipient subject will need to be approved before administration of convalescent plasma Recipient Exclusion Criteria: - Female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period - Receipt of pooled immunoglobulin in past 30 days - Contraindication to transfusion or history of prior reactions to transfusion blood products - Patients currently enrolled in other drug trials that preclude investigational treatment with anti-SARS-CoV-2 convalescent plasma

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
anti-SARS-CoV-2 convalescent plasma
Infusion of one unit of anti-SARS-CoV-2 convalescent plasma ~300 mL over 4 hours

Locations

Country Name City State
United States University of Chicago Medicine Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
University of Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Success of Administering Plasma Number of patients who receive convalescent plasma At time of administration
Primary Type of Respiratory Support Levels of respiratory support will be graded (e.g. room air, high flow oxygen, intubation) to determine the change in type of respiratory support at 28 days. Until discharge from hospital
Secondary Cardiac Arrest Number of patients experiencing cardiac arrest. 28 days after plasma administration
Secondary Transfer to ICU Number of patients transferred to ICU 28 days
Secondary ICU Mortality Number of patients dying in the ICU Until discharge
Secondary ICU Length of Stay This will be a continuous outcome defined by the amount of time between plasma administration and discharge from ICU. This will be treated as a time-to-event. Up to 50 days
Secondary Hospital Mortality Mortality during course of illness Until discharge
Secondary Hospital Length of Stay This will be a continuous outcome defined by the amount of time between plasma administration and discharge from hospital. Until discharge
Secondary Ventilator-free Days This will be a continuous outcome defined by the amount of time between plasma administration and the transition from mechanical ventilation to non-invasive respiratory support. 28 days
Secondary Overall Survival (28-day Mortality) 28-Day Overall Survival is defined as the status of the patient at the end of 28 days, beginning from the time of plasma administration. 28 days
See also
  Status Clinical Trial Phase
Completed NCT05065827 - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Recruiting NCT05359770 - Association of Inspiratory Muscle Training With HD-tDCS for Assistance to Patients With Long Covid-19 N/A
Completed NCT04515147 - A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 Phase 2
Not yet recruiting NCT06025812 - Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells) N/A
Recruiting NCT05289115 - Protocol for Assistance to Patients With Long Covid-19 Undergoing Treatment With HD-tDCS N/A
Completed NCT04779138 - Increasing Vaccine Uptake in Underresourced Public Housing Areas N/A
Completed NCT04953078 - A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19 Phase 1
Not yet recruiting NCT05868239 - Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study N/A
Completed NCT04690413 - NOWDx Test for the Detection of Antibodies to COVID-19 N/A
Completed NCT04818164 - Prone Position Improves End-Expiratory Lung Volumes in COVID-19 Acute Respiratory Distress Syndrome
Terminated NCT04530448 - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Phase 4
Completed NCT04572399 - UVA Light Device to Treat COVID-19 N/A
Recruiting NCT04610567 - Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19) Phase 1/Phase 2
Recruiting NCT04772170 - Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
Recruiting NCT04581954 - Inflammatory Signal Inhibitors for COVID-19 (MATIS) Phase 1/Phase 2
Completed NCT04405934 - COG-UK Project Hospital-Onset COVID-19 Infections Study N/A
Enrolling by invitation NCT04484025 - SPI-1005 Treatment in Moderate COVID-19 Patients Phase 2
Completed NCT05572840 - Wear Your Mask, Wash Your Hands, Don't Get COVID-19 N/A
Withdrawn NCT04838847 - A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19 Phase 3
Terminated NCT04371978 - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Phase 3